STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study

(2016) V.J. Ludbrook et al.   BRITISH JOURNAL OF DERMATOLOGY

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

(2015) R. Bissonnette et al.   BRITISH JOURNAL OF DERMATOLOGY

Psoriasis

(2014) P. Di Meglio et al.   Cold Spring Harbor Perspectives in Medicine

Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity

(2013) Rosa M. Andrés et al.   EXPERIMENTAL DERMATOLOGY

STAT1 expression and activation is increased in lesional psoriatic skin

(2012) A. Hald et al.   BRITISH JOURNAL OF DERMATOLOGY

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis

(2012) Naresh Punwani et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation

(2011) Jordan S. Fridman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice

(2009) B. Y. Chang et al.   JOURNAL OF IMMUNOLOGY

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antimicrobial peptides and self-DNA in autoimmune skin inflammation

(2008) Michel Gilliet et al.   CURRENT OPINION IN IMMUNOLOGY

Pro-inflammatory cytokine release in keratinocytes is mediated through the MAPK signal-integrating kinases

(2008) Rasmus Boye Kjellerup et al.   EXPERIMENTAL DERMATOLOGY

Type I Interferon: Potential Therapeutic Target for Psoriasis?

(2008) Yihong Yao et al.   PLoS One